Who Is Jody Aufrichtig? Chief Executive Officer of Psyence BioMed and TIRC

Where Jody Aufrichtig Is Now

Jody Aufrichtig holds executive leadership positions across Psyence BioMed and Texas Ibogaine Research Corporation (TIRC).

Executive Leadership at Psyence BioMed and TIRC

Jody Aufrichtig serves as Chief Executive Officer of Psyence BioMed (BioSpace) and serves as Chief Executive Officer of Texas Ibogaine Research Corporation (TIRC) (Business Insider).

Aufrichtig stated that TIRC was established in Texas to bring rights, pharmaceutical-grade supply, and development strategy together in a dedicated U.S. company for U.S. patients (Business Insider). He also stated that Psyence BioMed spent the preceding year establishing supply, manufacturing capability, and inventory to support clinical research (StreetInsider).

Manufacturing and Supply Partnerships

Aufrichtig stated that Benuvia brings a DEA-registered U.S. facility with the quota, systems, and track record required to manufacture controlled substances to pharmaceutical standards (BioSpace). He stated that the partnership with Benuvia, combined with planned licensed supply, has the potential to create an end-to-end pathway from pharmaceutical-grade source material through U.S.-based manufacturing (BioSpace).

Aufrichtig stated that the investment in PsyLabs and share exchange are intended to align Psyence BioMed more closely with required manufacturing and supply capabilities while TIRC advances the U.S. program (The Globe and Mail). Furthermore, Aufrichtig stated that the term sheet with PsyLabs was intended to give TIRC a defined position in U.S. ibogaine development backed by PsyLabs' material, know-how, and technical documentation (FinanzNachrichten).

Government and Strategic Engagement

Aufrichtig submitted a formal letter to President Donald J. Trump and HHS Secretary Robert F. Kennedy Jr. commending leadership in advancing psychedelic research initiatives (Nasdaq).

Aufrichtig stated that the objective of Psyence BioMed's U.S. visit was to share expertise and explain the specialized process needed to produce compliant pharmaceutical-grade ibogaine for regulated research (Nasdaq). He also stated that Psyence BioMed has prepared to help answer questions from government bodies and researchers on studying ibogaine safely and to pharmaceutical standards (Business Insider).

Statements on Ibogaine Development

Aufrichtig stated that access to pharmaceutical-grade ibogaine is fundamental to Psyence BioMed's planned U.S. program, and that the objective is to advance the program responsibly, supported by rigorous clinical research and pharmaceutical-grade manufacturing (The Globe and Mail).

Aufrichtig stated that regulatory signals confirm that ibogaine warrants rigorous, structured evaluation, and that discussion around ibogaine is no longer occurring at the margins of medicine (StreetInsider; Business Insider). He stated that there is a sense of urgency around ibogaine work, particularly for veterans, that Psyence BioMed was built to step forward and is ready to answer the call to help advance ibogaine, and that it intends to participate actively in future developments (Business Insider).

Aufrichtig stated that infrastructure and supply capabilities serve as the differentiator given the limited global availability of GMP-grade ibogaine, positioning Psyence BioMed to support both its own programs and the broader ecosystem as interest grows (StreetInsider). He also stated that for any federal agency, state program, or clinical partner, the question of who to work with on ibogaine in the U.S. has a clear answer (FinanzNachrichten).

Frequently asked questions